Channel Therapeutics Corp. Files 8-K with Material Agreements & Updates

Ticker: PTHS · Form: 8-K · Filed: 2025-04-17T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, equity-sale, corporate-update

TL;DR

Channel Therapeutics filed an 8-K detailing material agreements, equity sales, and accountant changes. Big moves happening.

AI Summary

On April 17, 2025, Channel Therapeutics Corp. (formerly Chromocell Therapeutics Corp.) entered into a material definitive agreement. The company also reported on unregistered sales of equity securities, changes in its certifying accountant, and submitted matters to a vote of security holders. This filing also includes Regulation FD disclosures and other events, along with financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate activity, including new agreements and potential shareholder votes, which could impact the company's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can introduce financial and regulatory risks.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Channel Therapeutics Corp. on April 17, 2025?

The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text snippet.

What was Channel Therapeutics Corp. formerly known as?

Channel Therapeutics Corp. was formerly known as Chromocell Therapeutics Corp., with a name change date of March 23, 2022.

What are the key items reported in this 8-K filing?

The key items reported include entry into a material definitive agreement, unregistered sales of equity securities, changes in the registrant's certifying accountant, submission of matters to a vote of security holders, Regulation FD disclosure, other events, and financial statements and exhibits.

In which state was Channel Therapeutics Corp. incorporated?

Channel Therapeutics Corp. was incorporated in Nevada.

What is the SIC code and industry classification for Channel Therapeutics Corp.?

The Standard Industrial Classification (SIC) code is 2836, and the industry classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

From the Filing

0001753926-25-000652.txt : 20250417 0001753926-25-000652.hdr.sgml : 20250417 20250417061148 ACCESSION NUMBER: 0001753926-25-000652 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20250417 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250417 DATE AS OF CHANGE: 20250417 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Channel Therapeutics Corp CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 863335449 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 25844253 BUSINESS ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 BUSINESS PHONE: 9176446313 MAIL ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 FORMER COMPANY: FORMER CONFORMED NAME: Chromocell Therapeutics Corp DATE OF NAME CHANGE: 20220323 8-K 1 g084777_8k.htm FORM 8-K Form 8-K false 0001919246 0001919246 2025-04-17 2025-04-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): April 17, 2025   Channel Therapeutics Corporation   (Exact name of registrant as specified in its charter)   Nevada   001-41964   86-3335449 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   4400 Route 9 South , Suite 1000 Freehold , NJ   07728 (Address of registrant’s principal executive office)   (Zip code)   Registrant’s telephone number, including area code: (877) 265-8266   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   CHRO   The NYSE American LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01. Entry into a Material Definitive Agreement   Merger Agreement   On April 16, 2025, Channel Therapeutics Corporation, a Nevada corporation (“ Channel ”), CHRO Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Ch

View on Read The Filing